Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIDES: Focused Ultrasound and Temozolomide in Pontine DMG
NCT07562971Phase 2Not yet recruiting
- Start
- May 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in diffuse midline glioma (DMG). Primary endpoints: Device and procedure related adverse events at 72 hours and 6-month progression-free survival at 12 months. Planned start May 2026; status: not yet recruiting.
02
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT07562971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562971.